PFE vs TNXP
PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas. TNXP: A commercial-stage biopharmaceutical company focused on CNS, immunology, and infectious disease therapies, headlined by its FDA-approved fibromyalgia treatment, TONMYA.
Side-by-side fundamentals
| Metric | PFE | TNXP | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $30.11 | $5.78 | |
| Market cap | $171.6B | $99M | |
| P/E as of 2026-10-20 | 39.62 | n/a | |
| Net margin FY2025, SEC XBRL | +12.4% | -946.2% | PFE higher |
| Operating margin FY2025, SEC XBRL | n/a | -959.1% | |
| ROE FY2025, SEC XBRL | +9.0% | -50.6% | PFE higher |
| ROA FY2025, SEC XBRL | +3.7% | -44.7% | PFE higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-28 | 0.74 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | -1.6% | +29.9% | TNXP higher |
| Revenue CAGR (3y) SEC XBRL | -14.8% | +29.9% | TNXP higher |
| Dividend yield as of 2026-09-02 | +6.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 11 | 0 | PFE higher |
| Beta as of 2026-09-02 | 0.38 | 1.07 | |
| 1-year return as of 2026-10-20 close | +22.0% | -70.9% | PFE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.